20 Best Performing Stocks Over the Last 20 Years
Twenty years can turn a good business into a very different investment.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 2,060 | $237,374 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.56 | 24,218 | $812,836.00 | 1,146,631 | 2026-03-17 | Filing | |
| $33.00 | 75,782 | $2,500,972.72 | 1,122,413 | 2026-03-17 | Filing | |
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $116.30 | 300 | $34,889.01 | 1,054,543 | 2026-10-15 | Filing | |
| $115.39 | 3,046 | $351,476.42 | 1,054,843 | 2026-10-15 | Filing | |
| $114.48 | 6,654 | $761,717.32 | 1,057,889 | 2026-10-15 | Filing | |
| $116.59 | 5,147 | $600,063.00 | 3,946 | 2026-10-02 | Filing | |
| $115.73 | 2,086 | $241,412.36 | 9,093 | 2026-10-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 73,375 | $8,064,632 | 0.01% | |
| 2. | 66,365 | $7,647,212 | 0.84% | |
| 3. | 41,424 | $4,773,288 | 0.11% | |
| 4. | 34,326 | $3,955,385 | 0.31% | |
| 5. | 32,267 | $3,718,126 | 0.01% |
News See All
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)
BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its second-quarter 2026 investor letter for “Buffalo Mid Cap Discovery Fund”.
Corcept's (CORT) Cancer Drug Just Cleared Europe's Toughest Hurdle
On September 18, Corcept Therapeutics (NASDAQ:CORT) said Europe's drug regulator recommended approval for the cancer therapy that has already earned a spot in US cancer treatment guidelines.
Bloom Energy Stock (BE) Is Rising 6% in Friday’s After-Hours Trading – Here’s Why
Bloom Energy ($BE) stock jumped about 6% in Friday’s extended trading session after the S&P Dow Jones Indices announced its addition to the S&P 500...
Blowing Past the Street: 46 Stocks That Crushed Q2 EPS Projections
More than 250 companies announced their earnings performance in the second quarter of the year on Wednesday, July 29, offering a fresh look at how they performed relative to what the market expected of...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript May 1, 2026 Operator: Thank you for standing by, and welcome to Corcept Therapeutics First Quarter 2026 Earnings Conference...
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli
Corcept Therapeutics Incorporated (NASDAQ:CORT) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
10 Best Biotech Stocks with Highest Upside Potential
In this article, we will take a look at some of the best biotech stocks that are currently offering attractive upside to investors. On April 16, reports from J.P.
7 Best Stocks to Buy for Short Term
In this article, we will take a look at the best stocks to buy for the short term. In a continuously evolving market, investing has become a game of timing and informed decision-making.
Hedge Fund Resource Center